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Purpose/Objective: Radiosurgery is nowadays a valid 
treatment option for patients with brain metastasis. In the 
last year the use of new drugs increases the life expectance 
of these patients and advances in oncologic technology allows 
accurate radiotherapy treatment with high dose delivery and 
sparing of normal tissue resulting in a higher disease control.  
We retrospectively analyzed the efficacy in patients who 
received GammaKnife radiosurgery (GKRS) at our institution. 
Materials and Methods: Between October 2012 and July 
2014, 187 brain metastases in 77 patients were treated with 
Gamma Knife single-fraction RS. Clinical demographic 
features and treatment data were collected.The rates of 
local and distant intracranial progression, predictors of 
individual tumor local control and overall survival were 
determined by statistical analysis. 
Results: The mean age was 63 years (range: 25-87 years). 
The most common tumor histologies were non-small cell lung 
cancer (44 %), breast cancer (16 %) and melanoma (10 %) . 
Forty patients (52%) had a single metastasis, eight patients 
had more than 4 metastases with a maximum of eleven 
lesions in one patient. The most part of patients (62%) were 
in RPA class II and 38 % in RPA class I. Fifteen patients (20%) 
received a previous treatment for brain metastases: five 
patients surgical resection, eight whole brain radiotherapy, 
and two received both surgery and whole brain. Radiosurgery 
doses ranged between 15 Gy for lesions in critical site such as 
brainstem and 24 Gy for lesions with dimension less than 1 
cm. Median survival after GKRS was 13.4 months (range: 0.2-
22.6 months). Median time to local progression was 5.6 
months (range: 0.2-22.6 months), with a local control rate of 
76.6% at 1 year. Distant brain control was 74% at one year. At 
univariate analysis we found that age older than 60 years 
correlate with worse local control compared to youngest 
patients but the difference was not statistically significant 
(p=0.07). Patients with more than four lesions treated had a 
significant higher risk of local relapse (p=0.0003), but this 
data was possibly related to a selection bias. No patients 
developed a symptomatic radiation-induced treatment 
change on follow up MRIs. 
Conclusions: GKRS appears to be a safe and an effective 
technique to treat single and multiple brain metastases. 
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Purpose/Objective: Not much is known about the natural 
history culminating in hemoptysis caused by aspergilloma 
(fungus ball) which colonizes caves of pulmonary tuberculosis 
previously acquired. Local treatment requires surgical 
resection in symptomatic cases, but in patients with surgical 
contraindications, radiotherapy has the potential to be 
effective, and less invasive. 
Materials and Methods: Twenty-one patients with chronic 
necrotizing pulmonary aspergillosis were treated with 
conventional external-beam radiotherapy with a dose of 20 
Gray, from 1990 to 2002. It is initially evaluated the time for 
the development of hemoptysis from the previous treatment 
of tuberculosis. Other outcomes were: change in 
performance status after 30 days of treatment, local failure-
free survival and overall survival. 
Results: The median time between the end of tuberculosis 
treatment and the development of hemoptysis due to 
aspergilloma was 9 years. With radiotherapy, there was 
general improvement and resolution of hemoptysis in all 
patients. During follow-up 4 failures occurred, with local 
failure-free survival of 82% at 5 years and overall survival of 
59% at 5 years. Two patients died from recurrence of 
hemoptysis and two were rescued (cavernostomy and re-
irradiation with 20 Gy). Presence of chronic obstructive 
pulmonary disease (p = 0.021) and female gender (p = 0.032) 
were significantly detrimental in relation to overall survival. 
No variable tested was related to local control. 
Conclusions: Radiation therapy can be considered an 
effective alternative therapy to control bleeding due to 
fungus ball can impact on disease-free survival. 
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Purpose/Objective: Radiation-induced alopecia in 
hypofractionated whole brain radiation therapy with 
simultaneous integrated boost (WBRT+SIB) is an understudied 
issue, even in RTOG 9508. However, this effect has a 
significant impact on the quality of life of patients. We have 
currently found a technical solution to this problem. Our 
current protocol for WBRT+SIB is presented and described, 
incluiding a retrospective review of the results in relation to 
radiation-induced alopecia. 
Materials and Methods: The protocol already implemented in 
our department is based on a frame-less procedure 
compatible with masks of type 35764/2MA/M (Orfit Industries 
N.V., Wijnegem, Belgium), submasks of eXaSkin (Anatomical 
Geometry S.L., Sevilla, Spain) and a resonance compatible 
frame eXaFrame (Anatomical Geometry S.L., Sevilla, Spain).  
CT and MR studies of 1mm slice thickness are acquired with 
similar length, position and inmovilization. The whole 
procedure and the resulting high quality fussion is ensured by 
the eXaFrame system. Treatments were designed using VMAT 
in Treatment System Planning Pinnacle V.9.2 (Philips N.V, 
Koninklijke Holland) with multiple arcs, and delivered with a 
linear accelerator Elekta Synergy (Elekta A.B., Stockholm, 
Sweden). The dose scheme used is the one reported by 
Lagerwaard: [WBRT(20Gy) + SIBmts (40Gy)]/5 fr. Patient 
positioning is verified daily using IGRT with Elekta XVI, before 
and after treatment. Before optimization is performed, some 
auxiliary volumes are created: a 3mm ring around 
calota,called Follicles, and a volume contracted 12mm from 
the outer one, called CPE. Two CCW VMAT arcs (178º to 60º 
and 300º to 182º) are added, with the following objectives: 
Follicles (EQD2max = 16 Gy, weight = 20; EQD2max = 5 Gy, 
